Advanced search
Publication Cover
Leukemia & Lymphoma Volume 57, 2016 - Issue 11
Submit an article Journal homepage
182
Views
2
CrossRef citations to date
0
Altmetric
Letters to the Editor

Pre- and post-treatment serum ferritin levels in patients with higher risk myelodysplastic syndromes receiving azacitidine

Erica TsangFaculty of Medicine, University of British Columbia, Vancouver, BC, Canada;
&
Heather A. LeitchDepartment of Hematology, St. Paul’s Hospital and the University of British Columbia, Vancouver, BC, CanadaCorrespondence[email protected]
Pages 2709-2711 | Received 30 Dec 2015, Accepted 14 Feb 2016, Published online: 16 Mar 2016

References

  • Steensma DP, Bennett JM. The myelodysplastic syndromes: diagnosis and treatment. Mayo Clinic proceedings. 2006;81:104–130. [Review].
  • Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25:3503–3510.
  • Malcovati L, Della Porta MG, Cazzola M. Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. Haematologica. 2006;91:1588–1590.
  • Pullarkat V. Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye? Blood. 2009;114:5251–5255.
  • Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20:2429–2440.
  • Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010;28:562–569.
  • Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the international working group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419–425.
  • Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189–199.
  • Vardiman JW. The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms. Chem Biol Interact. 2010;184:16–20. [Review].
  • Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–2088.
  • Nevill TJ. BCCA Protocol Summary for Therapy of Myelodysplastic Syndrome using Azacitidine. 2013; [cited 2015 Oct 10]. Available from: http://wwwbccancerbcca/chemotherapy-protocols-site/Documents/Leukemia-BMT/ULKMDSA_Protocol_1Nov2013pdf.
  • Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223–232.
  • Callens C, Coulon S, Naudin J, et al. Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia. J Exp Med. 2012;207:731–750.
  • Chan LSA, Gu LC, Rauh JJ, et al. Iron overload accelerates development of leukaemia: evidence from a mouse model. Blood. 2010;116:59a–60a.
  • Zipperer E, Post JG, Herkert M, et al. Serum hepcidin measured with an improved ELISA correlates with parameters of iron metabolism in patients with myelodysplastic syndrome. Ann Hematol. 2013;92:1617–1623.
  • Santini V, Girelli D, Sanna A, et al. Hepcidin levels and their determinants in different types of myelodysplastic syndromes. PLoS One. 2011;6:e23109.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.